Table 2.

Description of dosing groups in the study

Treatment	Route	Number of subjects who received treatment	Formulation
A	IM	12	Dexamethasone phosphate solution (Fresenius Kabi USA LLC)
B	IM	12	Betamethasone phosphate solution (BETENESOL®, Glaxo SmithKline Pharmaceuticals Ltd, India)
C	IM	24	Betamethasone phosphate (3 mg) and acetate (3 mg) suspension (Celestone®, Merck and Co., Inc., USA)
D	PO	24	0.5 mg dexamethasone phosphate tablets (Cadila Healthcare Ltd, India)
E	PO	24	0.5 mg betamethasone phosphate tablets (BETNESOL®, Glaxo SmithKline Pharmaceuticals Ltd, India)

There were 6 subjects in each treatment group and each subject received two treatments. Total doses were all 6 mg